Innovation

Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.

Inaugural artificial intelligence recommendations from NICE on radiotherapy contouring should allow clinicians to spend more time with patients and on complex cases where AI is not an option. But large language models are not appropriate in all cases, cautions Adrian Sutherland, principal healthcare architect at Endava consultancy.

Mapping the patient journey uncovers a wealth of insights into care, diagnosis and intervention. The onset of advanced analytics tools and sensors now augment the pharma industry’s understanding of the challenges of traversing health care systems. Layering AI into the mapping process not only has the power to provide insights into the current clinical pathway, it can be used to predict and intervene in clinical care.

Hyfe is extending AI to acoustics and championing technology it claims can transform the approach to cough management, leading to improved diagnoses, better treatment and superior health outcomes. CMO Peter Small explained the rationale and how AI has inspired a significant leap forward.

Podcast: Mithra is shaking up the stagnant women’s health market with a brand new estrogenic compound. E4, or estetrol, is a natural estrogen produced by the human fetus during pregnancy, and could represent a major breakthrough in contraceptive and menopause care.

Biomedical engineering graduate Cécile Dupont has for the past 12 years helped healthcare technology businesses develop disruptive solutions that positively impact patients’ lives. The current chapter of her career opened in 2017 when she joined Sofinnova MD Start, the early-stage medtech incubator of VC investor Sofinnova Partners, where she is a partner.

In an environment replete with pricing and patient access pressures, top biopharma companies are building commercialization models that emphasize inclusive and diverse decision-making and that integrate digital tools with a human salesforce.

With a growing focus on clinical trial diversity, companies are looking for ways to recruit from historically marginalized communities. Machine learning may help meet these diversity goals. 

One issue that has surfaced as the pharmaceutical industry responds to the US FDA’s recent discussion paper on manufacturing with AI machine learning models is the question of how to explain what the models are doing.

Many use cases potentially suit AliveCor’s smartphone-based ECG device, which delivers medical-grade cardiac data to consumers, patients and doctors on demand. Artificial intelligence is just one element of the technology offering, says the company’s VP, EMEA Stefan Holzer.

Bad actors, lack of funding and skilled workforce shortages threaten to hinder the growth of cell and gene therapies. To unleash the transformative power of cell and gene therapies requires the concerted effort of the entire CGT community.

Staff burnout, workforce attrition and patient backlogs are testing the resiliency of health systems. Crisis is not too big a word. Against this backdrop, GE HealthCare commissioned a major report, Reimagining Better Health 2023, which suggested ways of increasing trust and confidence in healthcare provider systems as they evolve.

Israeli start-up 9xchange is removing some of the friction from the asset sale and acquisition process through its digital marketplace. A partnership with BenevolentAI is also helping users identify repurposing or indication expansion opportunities. In Vivo spoke with 9xchange CEO Anat Naschitz and Benevolent AI's Matthew Fujisawa.    

Through an Israeli innovation lab, four big pharma companies are fostering AI-driven start-ups to help solve industry problems.

Repurposing licensed drugs can be an affordable and effective way to bring new treatments to market, but initial efforts tend to lack funding from big pharma. In Vivo takes a closer look at repurposing projects across the central nervous system space, what it is that drives the work forward and how innovative trial design is changing the game.